Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A trial of axatilimab in combination with a JAK inhibitor in patients with steroid-refractory cGVHD

Next Previous
Trial Profile

A trial of axatilimab in combination with a JAK inhibitor in patients with steroid-refractory cGVHD

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axatilimab (Primary) ; Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors Syndax Pharmaceuticals

Most Recent Events

  • 01 Aug 2023 According to an Incyte Corporation media release, this trial is planned to initiate by year-end 2023.
  • 07 Feb 2023 According to an Incyte Corporation media release, this trial is expected to initiate later this year.
  • 01 Nov 2022 According to an Incyte Corporation media release, this trial is expected to initiate in the first quarter of 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top